1. Kennedy, W.R., Alter, M., and Sung, J.H. (1968). Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671–680.
2. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fischbeck, K.H. (1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79.
3. Sahashi, K., and Katsuno, M. (2018). Pathogenesis of Polyglutamine Diseases. Published online October 15, 2018. 101002/9780470015902.a0021486.pub2.
4. Lieberman, A.P., Shakkottai, V.G., and Albin, R.L. (2019). Polyglutamine Repeats in Neurodegenerative Diseases. Annu. Rev. Pathol. 14, 1–27.
5. Wild, E.J., and Tabrizi, S.J. (2017). Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 16, 837–847.
6. Gonzalez-Alegre, P. (2019). Recent advances in molecular therapies for neurological disease: triplet repeat disorders. Hum. Mol. Genet. 28 (R1), R80–R87.
7. Silva, A.C., Lobo, D.D., Martins, I.M., Lopes, S.M., Henriques, C., Duarte, S.P., Dodart, J.-C., Nobre, R.J., and Pereira de Almeida, L. (2020). Antisense oligonucleo- tide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain 143, 407–429.
8. Fiszer, A., and Krzyzosiak, W.J. (2014). Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787–6810.
9. Hu, J., Matsui, M., Gagnon, K.T., Schwartz, J.C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., and Corey, D.R. (2009). Allele-specific silencing of mutant hunting- tin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27, 478–484.
10. Gagnon, K.T., Pendergraff, H.M., Deleavey, G.F., Swayze, E.E., Potier, P., Randolph, J., Roesch, E.B., Chattopadhyaya, J., Damha, M.J., Bennett, C.F., et al. (2010). Allele- selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166–10178.
11. Fiszer, A., Mykowska, A., and Krzyzosiak, W.J. (2011). Inhibition of mutant hunting- tin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res. 39, 5578–5585.
12. Hu, J., Liu, J., and Corey, D.R. (2010). Allele-selective inhibition of huntingtin expres- sion by switching to an miRNA-like RNAi mechanism. Chem. Biol. 17, 1183–1188.
13. Liu, J., Pendergraff, H., Narayanannair, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Hu, J., and Corey, D.R. (2013). RNA duplexes with abasic sub- stitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expres- sion. Nucleic Acids Res. 41, 8788–8801.
14. Aiba, Y., Hu, J., Liu, J., Xiang, Q., Martinez, C., and Corey, D.R. (2013). Allele-selec- tive inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. Biochemistry 52, 9329–9338.
15. Hu, J., Liu, J., Narayanannair, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Swayze, E.E., Lima, W.F., Prakash, T.P., et al. (2014). Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 53, 4510–4518.
16. Sun, X., Marque, L.O., Cordner, Z., Pruitt, J.L., Bhat, M., Li, P.P., Kannan, G., Ladenheim, E.E., Moran, T.H., Margolis, R.L., and Rudnicki, D.D. (2014). Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum. Mol. Genet. 23, 6302–6317.
17. Datson, N.A., González-Barriga, A., Kourkouta, E., Weij, R., van de Giessen, J., Mulders, S., Kontkanen, O., Heikkinen, T., Lehtimäki, K., and van Deutekom, J.C.T. (2017). The expanded CAG repeat in the huntingtin gene as target for thera- peutic RNA modulation throughout the HD mouse brain. PLoS ONE 12, e0171127.
18. Kourkouta, E., Weij, R., González-Barriga, A., Mulder, M., Verheul, R., Bosgra, S., Groenendaal, B., Puoliväli, J., Toivanen, J., van Deutekom, J.C.T., and Datson, N.A. (2019). Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide. Mol. Ther. Nucleic Acids 17, 601–614.
19. Liu, C.R., and Cheng, T.H. (2015). Allele-selective suppression of mutant genes in polyglutamine diseases. J. Neurogenet. 29, 41–49.
20. Saudou, F., and Humbert, S. (2016). The Biology of Huntingtin. Neuron 89, 910–926.
21. Rué, L., Bañez-Coronel, M., Creus-Muncunill, J., Giralt, A., Alcalá-Vida, R., Mentxaka, G., Kagerbauer, B., Zomeño-Abellán, M.T., Aranda, Z., Venturi, V., et al. (2016). Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels. J. Clin. Invest. 126, 4319–4330.
22. Snead, N.M., Escamilla-Powers, J.R., Rossi, J.J., and McCaffrey, A.P. (2013). 50 un- locked nucleic acid modification improves siRNA targeting. Mol. Ther. Nucleic Acids 2, e103.
23. Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., and Sobue, G. (2002). Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843–854.
24. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., and Bates, G.P. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506.
25. Dragatsis, I., Goldowitz, D., Del Mar, N., Deng, Y.P., Meade, C.A., Liu, L., Sun, Z., Dietrich, P., Yue, J., and Reiner, A. (2009). CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington’s disease transgenic mouse. Neurobiol. Dis. 33, 315–330.
26. Wang, C.E., Tydlacka, S., Orr, A.L., Yang, S.H., Graham, R.K., Hayden, M.R., Li, S., Chan, A.W.S., and Li, X.J. (2008). Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Hum. Mol. Genet. 17, 2738–2751.
27. Yang, H., Yang, S., Jing, L., Huang, L., Chen, L., Zhao, X., Yang, W., Pan, Y., Yin, P., Qin, Z.S., et al. (2020). Truncation of mutant huntingtin in knock-in mice demon- strates exon1 huntingtin is a key pathogenic form. Nat. Commun. 11, 2582.
28. Lieberman, A.P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X.X., Cortes, C.J., Bennett, C.F., Monia, B.P., et al. (2014). Peripheral androgen receptor gene suppres- sion rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 7, 774–784.
29. Cortes, C.J., Ling, S.C., Guo, L.T., Hung, G., Tsunemi, T., Ly, L., Tokunaga, S., Lopez, E., Sopher, B.L., Bennett, C.F., et al. (2014). Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82, 295–307.
30. Langkjaer, N., Pasternak, A., and Wengel, J. (2009). UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17, 5420–5425.
31. Hu, J., Liu, J., Yu, D., Chu, Y., and Corey, D.R. (2012). Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: func- tion through the RNAi pathway. Nucleic Acids Res. 40, 11270–11280.
32. Ledford, H. (2018). Gene-silencing technology gets first drug approval after 20-year wait. Nature 560, 291–292.
33. Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K.N., Jayaraman, M., Rajeev, K.G., Cantley, W.L., Dorkin, J.R., et al. (2010). Targeted de- livery of RNAi therapeutics with endogenous and exogenous ligand-based mecha- nisms. Mol. Ther. 18, 1357–1364.
34. Cullis, P.R., and Hope, M.J. (2017). Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 25, 1467–1475.
35. Rungta, R.L., Choi, H.B., Lin, P.J.C., Ko, R.W.Y., Ashby, D., Nair, J., Manoharan, M., Cullis, P.R., and Macvicar, B.A. (2013). Lipid nanoparticle delivery of sirna to silence neuronal gene expression in the brain. Mol. Ther. Nucleic Acids 2, e136.
36. Shyam, R., Ren, Y., Lee, J., Braunstein, K.E., Mao, H.Q., and Wong, P.C. (2015). Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol. Ther. Nucleic Acids 4, e242.
37. Helmschrodt, C., Höbel, S., Schöniger, S., Bauer, A., Bonicelli, J., Gringmuth, M., Fietz, S.A., Aigner, A., Richter, A., and Richter, F. (2017). Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce a-Synuclein Expression in a Model of Parkinson’s Disease. Mol. Ther. Nucleic Acids 9, 57–68.
38. Bartlett, D.W., and Davis, M.E. (2006). Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322–333.
39. Omi, K., Tokunaga, K., and Hohjoh, H. (2004). Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 558, 89–95.
40. Katsuno, M., Tanaka, F., Adachi, H., Banno, H., Suzuki, K., Watanabe, H., and Sobue, G. (2012). Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog. Neurobiol. 99, 246–256.
41. Sahashi, K., Katsuno, M., Hung, G., Adachi, H., Kondo, N., Nakatsuji, H., Tohnai, G., Iida, M., Bennett, C.F., and Sobue, G. (2015). Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 24, 5985–5994.
42. Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J.B., Karmali, P.P., Chivukula, P., and Verma, I.M. (2017). Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl. Acad. Sci. USA 114, E1941–E1950.
43. Onodera, K., Shimojo, D., Ishihara, Y., Yano, M., Miya, F., Banno, H., Kuzumaki, N., Ito, T., Okada, R., de Araújo Herculano, B., et al. (2020). Unveiling synapse pathology in spinal bulbar muscular atrophy by genome-wide transcriptome analysis of purified motor neurons derived from disease specific iPSCs. Mol. Brain 13, 18.
44. Iida, M., Sahashi, K., Kondo, N., Nakatsuji, H., Tohnai, G., Tsutsumi, Y., Noda, S., Murakami, A., Onodera, K., Okada, Y., et al. (2019). Src inhibition attenuates poly- glutamine-mediated neuromuscular degeneration in spinal and bulbar muscular at- rophy. Nat. Commun. 10, 4262.
45. Sahashi, K., Hua, Y., Ling, K.K.Y., Hung, G., Rigo, F., Horev, G., Katsuno, M., Sobue, G., Ko, C.P., Bennett, C.F., and Krainer, A.R. (2012). TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. Genes Dev. 26, 1874–1884.